Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1042/ETLS20190194 http://scihub22266oqcxt.onion/10.1042/ETLS20190194 32463087!ä!32463087 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Emerg+Top+Life+Sci 2020 ; 4 (2): 129-136 Nephropedia Template TP {{tp|p=32463087|t=2020. Antimicrobial resistance: the good, the bad, and the ugly |pdf=|usr=}}{{32463087}} gab.com Text Antimicrobial resistance: the good, the bad, and the ugly JO: Emerg Top Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32463087 #FOAvip As the Royal Society for Biology (RSB) was forming 10 years ago, antimicrobial resistance (AMR) was being heralded as the next threat with a magnitude on a par with global warming. Just a few years later, in 2016, Jim O'Neill's report was published laying out recommendations for tackling drug-resistant infections globally. Where are we now, and what are the challenges ahead? As a slow burner, how will the impact of AMR compare against the recent rapid devastation of the COVID-19 pandemic, and how can we channel some of the good things that come from it (like the awareness and technique of effective hand hygiene) to help us combat AMR speedily and definitively? Twit Text FOAVip Antimicrobial resistance: the good, the bad, and the ugly ????Emerg Top Life Sci http://www.kidney.de/pget.php?&tw=1&pmid=32463087 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32463087 #FOAvip English Wikipedia <ref>{{Cite pmid|32463087}}</ref> Antimicrobial resistance: the good, the bad, and the ugly #MMPMID32463087 Hardie KR Emerg Top Life Sci 2020[Sep]; 4 (2): 129-136 PMID32463087show ga As the Royal Society for Biology (RSB) was forming 10 years ago, antimicrobial resistance (AMR) was being heralded as the next threat with a magnitude on a par with global warming. Just a few years later, in 2016, Jim O'Neill's report was published laying out recommendations for tackling drug-resistant infections globally. Where are we now, and what are the challenges ahead? As a slow burner, how will the impact of AMR compare against the recent rapid devastation of the COVID-19 pandemic, and how can we channel some of the good things that come from it (like the awareness and technique of effective hand hygiene) to help us combat AMR speedily and definitively? |Anti-Bacterial Agents/*pharmacology[MESH] |Bacterial Infections/*drug therapy[MESH] |Betacoronavirus/drug effects[MESH] |Biofilms[MESH] |COVID-19[MESH] |Coronavirus Infections/drug therapy/prevention & control[MESH] |Drug Resistance, Bacterial/*drug effects[MESH] |Humans[MESH] |Infection Control[MESH] |Klebsiella pneumoniae/drug effects[MESH] |Pandemics/prevention & control[MESH] |Pneumonia, Viral/drug therapy/prevention & control[MESH] |Public Health[MESH]Antimicrobial resistance: the good, the bad, and the ugly (epmc).pdf DeepDyve Pubget Overpricing